News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent to see that RENB is moving forward with the financial aspects of this excellent agreement to significantly expand their capabilities on advanced cancer methodologies.
From today's news:
By adding Predictive’s AI-driven drug discovery platform, vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data to Renovaro’s multi-disciplinary artificial intelligence, multi-omic and multi-modal data expertise, the combined company will be positioned to commercialize its drug discovery and diagnostic platforms.
$RENB NEWS: Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Renovaro Inc
Mon, March 3, 2025 at 9:15 AM EST
In This Article: POAI, RENB
Renovaro Inc
Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States
Renovaro’s Strategic Acquisition of BioSymetrics Vastly Expands Biomarker and Drug Discovery Opportunities and the Development of Diagnostic Applications in Oncology
LOS ANGELES, March 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has advanced the first tranche of financing to Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States.
By adding Predictive’s AI-driven drug discovery platform, vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data to Renovaro’s multi-disciplinary artificial intelligence, multi-omic and multi-modal data expertise, the combined company will be positioned to commercialize its drug discovery and diagnostic platforms.
“Since we first announced our intentions to merge with Predictive Oncology in January, we have worked diligently to thoroughly evaluate the expanded market opportunities created by this merger and the recent merger agreement with BioSymetrics,” said David Weinstein, CEO of Renovaro. “We are committed to building a world class diagnostics and discovery company, underscored by our recent $15 million in additional equity committed to accelerate our focus on revolutionizing healthcare. This first tranche of financing represents diligent progress toward a definitive agreement. By combining the capabilities of Predictive Oncology, BioSymetrics and RenovaroCube we will have a solid AI stack and an end-to-end solution for biomarker discovery and validation for precision medicine.”
Raymond Vennare, Chairman and Chief Executive Officer of Predictive Oncology added, “The recent acquisition of BioSymetrics, and our ability to launch ChemoFx in Europe, represent a significant step forward in our efforts. Although we have been working well together over the past two months, the complicated logistics of combining these technologies and international teams still requires a bit more effort, but we fully expect to be signing a definitive agreement within the next few weeks.”
The current transaction involves issuing each Predictive Oncology shareholder an 18-month $3 Redeemable Preferred share. Predictive Oncology does not intend to discuss or disclose further developments regarding these discussions unless and until its Board of Directors has approved a transaction or otherwise determined that further disclosure is appropriate or required by law.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s proprietary AI/ML platform has been scientifically validated to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development. For more information, visit www.renovarogroup.com.
Good morning $RENB!
$RENB $1.02 HOD $1.16 holding weekly gains on news: Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine https://finance.yahoo.com/news/renovaro-biosymetrics-announce-definitive-merger-182500352.html
David Weinstein, Chief Executive Officer of Renovaro (Nasdaq: RENB) commented, “We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery.”
$RENB 1.03 +33.25% Chart is Bullish on NEWS!
$RENB News: Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Renovaro Inc
Wed, February 26, 2025 at 1:25 PM EST
In This Article:
RENB
+30.66%
Renovaro Inc
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond
LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro’s data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas.
At the core of this collaboration is BioSymetrics’ proprietary Elion platform, a cutting-edge AI and machine learning engine that uncovers complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics’ Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite and improve target and biomarker identification and enable patient stratification and drug repurposing. BioSymetrics’ advanced AI in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle biological responses with unprecedented accuracy. Through in vivo modeling BioSymetrics has amassed an incredible database of proprietary in vivo experimentation, with associated behavioural and morphological analysis. This integrated approach hastens the discovery and validation of transformative therapeutics by bridging computational insights with real-world biological validation, and has enabled platform and analytic partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. By integrating Elion into Renovaro’s workflow, the combined entity aims to streamline the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development.
“This merger represents a pivotal step in our mission to diagnose cancer and advance precision medicine,” said David Weinstein, CEO of Renovaro. “By combining our expertise in oncology with BioSymetrics’ AI-driven biomarker discovery, we are creating a powerful synergy that will enhance our ability to identify new therapeutic targets, validate diagnostics and accelerate drug development.”
BioSymetrics’ AI technology has been instrumental in uncovering novel disease signatures and optimizing precision medicine strategies. Through this merger, Renovaro will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions.
“We are excited to join forces with Renovaro to translate cutting-edge biomarker discoveries into tangible advancements in drug development,” said Anthony Iacovone, CEO of BioSymetrics. “Our AI-driven Elion platform is significantly impacting precision medicine and by aligning with Renovaro’s deep expertise in immunotherapy and oncology, we can accelerate the journey from discovery to clinical application.”
The merger underscores a shared commitment to harnessing AI and data-driven approaches to improve patient outcomes. Moving forward, the combined company will focus on integrating AI-powered biomarker discovery with innovative drug development, ultimately bringing more precise and effective treatments to patients worldwide.
The transaction is expected to close in March 2025, subject to customary closing conditions and regulatory approvals.
For more information, visit www.renovarogroup.com and www.biosymetrics.com.
About BioSymetrics
BioSymetrics is a leading AI-powered drug discovery and data analytics company, focusing on phenotype-based insights to identify novel therapeutics. Its proprietary Elion platform integrates large-scale biological and clinical data to drive innovation in the pharmaceutical and healthcare industries. For more information, visit www.biosymetrics.com.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development. For more information, visit www.renovarogroup.com.
Great day here on $RENB
$RENB News: Renovaro Announces $15 million in Equity Committed
LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announces that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.
David Weinstein, Chief Executive Officer of Renovaro, commented, “We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery.”
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com
https://www.globenewswire.com/newsroom/ti?nf=OTM4NTEyOCM2Nzc5ODcxIzIxMjA2Nzk=
https://ml.globenewswire.com/media/NzUxYjk5NTEtY2QzZC00YWY3LWI0MGMtYTY5MjRhMGMzNjEzLTExMzIyNTA=/tiny/Renovaro-Inc.png
NEWS: Renovaro to Acquire Predictive Oncology in All-Stock Transaction
Renovaro Inc
Mon, January 6, 2025 at 9:15 AM EST 5 min read
In This Article:
RENB
+21.35%
POAI
+30.43%
Renovaro Inc
Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data
Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul
Combines Predictive Oncology’s AI-driven multi-omic drug discovery platform with Renovaro’s AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug discovery
Planned test launch to assist physicians in individualizing cancer therapy to improve treatment outcomes
LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced it has entered into a binding LOI to acquire Predictive Oncology (NASDAQ: POAI) in an all-stock transaction.
David Weinstein, Chief Executive Officer of Renovaro, commented, “Renovaro is on a quest to offer cancer patients early diagnostic options, treatment protocols, and recurrence monitoring. Predictive Oncology will enhance our capabilities by assisting oncologists with patient specific diagnostic and therapeutic clinical support data. Predictive Oncology’s proprietary AI/ML platform has been proven to predict tumor-drug response with 92% accuracy which, I believe, will allow us to launch as a decision support platform for medical oncologists in 2025. As importantly, there are strong synergies with Predictive’s small molecule solid tumor drug-tumor response modeling capabilities and Renovaro’s liquid biopsy approach to early cancer detection and monitoring.”
Raymond Vennare, Chief Executive Officer of Predictive Oncology, added, “We recognize that by integrating Predictive Oncology’s AI-driven drug discovery platform and vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data with Renovaro’s multi-disciplinary artificial intelligence, multi-omics and multi-modal data expertise, we are opening to door to diagnostic, therapeutic and drug discovery possibilities that we otherwise would never have considered.”
Short-Term Synergies
By leveraging Predictive Oncology’s extensive biobank of 150,000 tumor samples, Renovaro gains an invaluable resource to accelerate biomarker discovery, clinical trial optimization and clinical decision support tools across multiple cancer types.
The combined organization will have a state-of-the-art CLIA, NYSDOH, and CA-certified laboratory staffed by a highly experienced team.
Infrastructure streamlines Renovaro’s development, validation, and rollout of new diagnostic tests in Europe, improving speed to market and expanding global reach.
Introduces novel in vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy to the European markets.
Enables the company to collaborate across multi-omic platforms for drug discovery.
Long-Term Vision
Renovaro’s partnership with Predictive Oncology creates a powerful foundation for delivering a global point-of-care solution for cancer.
By integrating Predictive Oncology’s AI-driven small molecule solid tumor expertise with Renovaro’s AI-powered liquid biopsy and cancer vaccine programs, we envision an opportunity to provide patients with a comprehensive, end-to-end solution from diagnostics and early detection to personalized therapies, in silico modeling and biomarker discovery.
First-in-class, full-stack clinical service has the potential to advance cancer therapy at every stage of the patient’s journey, improving outcomes and reducing costs.
Predictive Oncology announced on November 13, 2024, that the company’s Board of Directors, working with a strategic advisor, had initiated a process to evaluate a broad range of strategic alternatives intended to maximize shareholder value and issued an update on December 3, 2024, stating the Company was engaged in productive discussions with multiple interested parties and looked forward to the timely completion of this process.
Transaction Details
Renovaro will acquire 100% of Predictive Oncology common shares through the issuance of Preferred stock.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s proprietary AI/ML platform has been scientifically validated to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA. https://predictive-oncology.com/
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com and STarsh@Renovarogroup.com
$RENB News: Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization
LOS ANGELES and AMSTERDAM, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced Chairman of the Board, Maurice van Tilburg, has been appointed as Chief Executive Officer of its subsidiary GEDi Cube BV (a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies) DBA RenovaroCube.
Maurice van Tilburg has held several senior positions in the Financial Services industry and Tech enterprises combining general management, technology, operational service delivery, financial management, audit and product development. In conjunction with the appointment, Mr. van Tilburg recently retired as the Director of the Dutch National Growth Fund where he oversaw a total of more than €11B covering the largest portfolio of government investments in the area of innovation and technology. With this new role he builds on his role at Techleap.nl where he developed new and additional sources of funding for Dutch Tech scale-ups in order to contribute to global challenges, economic growth, technology capabilities and employment in the Netherlands. Mr. van Tilburg brings with him his experience as CEO of Euronext Amsterdam where he was responsible for clients, product development, organization and P&L for the Dutch market as well as the operational running of all European stock markets of Euronext. In that context Mr. van Tilburg has also held nonexecutive/advisory board member positions at several startup companies.
“We are privileged that our Chairman Maurice van Tilburg has accepted the position of Chief Executive Officer of GEDi Cube BV, bringing a deep understanding of both Renovaro and GEDi Cube BV,” said David Weinstein, Chief Executive Officer of Renovaro. “His expertise in technology and the capital markets will enable us to prioritize commercializing our technologies. He will take the lead in partnerships with Nebul to advance the early detection of cancer and other diseases, and the Lumina project which aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for lung cancer. Maurice will be instrumental in steering us in our next stage of growth and GEDi Cube’s BV development pipeline to create value streams from a broad range of products and services.”
"I am thrilled to have the opportunity to lead GEDi Cube BV into its next exciting phase of development,” said Maurice van Tilburg “I believe that the transformative AI Cube platform will be an inflection point in the creation of diagnostics for early-stage cancer and identifying new genes for our Cancer Vaccine Platform. I look forward to working closely with the GEDiCube executive team to harness the power of multi-omics biomarkers and AI-driven technology with the aim to transform recurrence risk prediction and treatment strategies for millions of patients worldwide.”
Renovaro’s Board of Directors unanimously approved the appointment of Maurice van Tilburg as CEO of GEDi Cube BV.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
About GEDi Cube BV
DBA RenovaroCube is a pioneer in AI-based molecular diagnostics, committed to revolutionizing healthcare through advanced data analysis. Its platform integrates cutting-edge AI capabilities with state-of-the-art HPC infrastructure to provide unparalleled insights into multi-omic data for early detection of diseases based on non-invasive testing using liquid biopsy(blood)
RenovaroCube’s AI platform is purpose-built to process and analyze multi-omic molecular data, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. Originally developed for the fintech sector, this platform is being reengineered for healthcare, offering:
Sequence Processing: Transform raw molecular data from patient samples into clean, analyzable formats using advanced sequencing and alignment technologies, ensuring the highest quality for downstream analysis.
Biomarker Discovery: Harness unique algorithms and multi-omic pipelines to identify biologically relevant cancer biomarkers, providing critical insights into disease mechanisms and potential therapeutic targets.
AI Factory: Employ sophisticated machine learning models to predict cancer presence, origin, and stage based on extracted biomarker features. These models are trained on vast datasets to enhance accuracy and reliability, supporting early detection and personalized treatment strategies.
Precision Diagnostics: Offer an interactive interface for visualizing data, generating comprehensive clinical reports, and delivering actionable insights across various omic layers and biomarkers. This interface empowers healthcare professionals to make informed decisions with confidence.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com and STarsh@Renovarogroup.com
https://www.globenewswire.com/newsroom/ti?nf=OTMyNDkyNyM2NjcyNTEyIzIxMjA2Nzk=
https://ml.globenewswire.com/media/NDA4MWU4MzMtMzgzMC00ZDQ5LTk0NmQtOGMzNzU3MWMwNTA2LTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
NEWS: RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program
Renovaro Inc
Mon, December 23, 2024 at 9:00 AM EST 6 min read
In This Article:
RENB
+6.15%
Renovaro Inc
LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI
LOS ANGELES and AMSTERDAM, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary RenovaroCube (the ‘Cube’), a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, together with its consortium partners Flomics Biotech, Uppsala Universitet and Oncodia, received grant funding approval for the Lumina project from the Eurostars funding program after review by an independent expert panel.
Eurostars is part of the European Partnership on Innovative SMEs (Small and Medium-sized Enterprises). The partnership is co-funded by the European Union through Horizon Europe. Eurostars is the largest international funding program for SMEs wishing to collaborate on R&D projects that create innovative products, processes or services for commercialization, with over €250M in expected public-private investment each year.
The Lumina project aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for lung cancer. Harnessing the power of multi-omics biomarkers and AI-driven technology, this platform aims to transform recurrence risk prediction and treatment strategies for millions of patients worldwide.
“This award further validates our purpose-built AI platform in facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization,” said David Weinstein, Chief Executive Officer of Renovaro. “In partnership with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech, the Lumina project is focused on improving lung cancer patient survival. Over 5.7 million lung cancer cases are treated or monitored globally each year, and of all curatively treated lung cancer patients, 60% will relapse. Lumina represents a significant opportunity to address this critical issue, and we look forward to continuing work with our partners to bring this product to market.”
A High-Performance Platform for Better Outcomes
The objective of the LUMINA project is to develop a cutting-edge platform designed to provide unparalleled accuracy in detecting minimal residual disease. To achieve this, liquid biopsies combined with multi-omics biomarker technology, represent a revolutionary approach. The LUMINA project’s AI-powered platform capitalizes on this potential, aiming to provide a highly accurate, non-invasive solution that addresses a critical unmet need in lung cancer care.
Collaborative Expertise
The LUMINA project is built on a strong foundation of collaboration with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech. These partnerships bring together world-class clinical expertise and a multi-omic approach, leveraging the analysis of cell-free DNA and RNA to ensure the platform’s success.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
About RenovaroCube
RenovaroCube is a pioneer in AI-based molecular diagnostics, committed to revolutionizing healthcare through advanced data analysis. Its platform integrates cutting-edge AI capabilities with state-of-the-art HPC infrastructure to provide unparalleled insights into multi-omic data for early detection of diseases based on non-invasive testing using liquid biopsy (blood).
RenovaroCube’s AI platform is purpose-built to process and analyze multi-omic molecular data, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. Originally developed for the fintech sector, this platform is being reengineered for healthcare, offering:
Sequence Processing: Transform raw molecular data from patient samples into clean, analyzable formats using advanced sequencing and alignment technologies, ensuring the highest quality for downstream analysis.
Biomarker Discovery: Harness unique algorithms and multi-omic pipelines to identify biologically relevant cancer biomarkers, providing critical insights into disease mechanisms and potential therapeutic targets.
AI Factory: Employ sophisticated machine learning models to predict cancer presence, origin, and stage based on extracted biomarker features. These models are trained on vast datasets to enhance accuracy and reliability, supporting early detection and personalized treatment strategies.
Precision Diagnostics: Offer an interactive interface for visualizing data, generating comprehensive clinical reports, and delivering actionable insights across various omic layers and biomarkers. This interface empowers healthcare professionals to make informed decisions with confidence.
About Flomics Biotech, S.L.
Flomics https://www.flomics.com/ is a fast-growing biotech company based in Barcelona, operating in the genomics and liquid biopsy space. Flomics’ objective is to develop a revolutionary diagnostic blood test based on Next-Generation Sequencing (NGS) of cell-free RNA, suitable for the early detection of different complex diseases, in particular cancer. Additionally, as CRO, Flomics also offers the following services: biomarker discovery (on tissue and biofluids), support on bioinformatic analysis and an intuitive web-based platform suitable for the analysis of NGS data (Stratus). The team at Flomics has a strong background in RNA and liquid biopsy, as well as advanced bioinformatics analysis methods.
About Uppsala Universitet
Uppsala University is the first university in the Nordic countries and a world-class research institution. The Department of Immunology, Genetics and Pathology is dedicated to advancing cancer diagnostics and treatment through the study of molecular changes associated with cancer. The research aims to harness measurable molecular information to improve diagnosis and therapy, with a strong focus on developing liquid biopsy-based diagnostic tests. A key initiative is the U-CAN project, which provides a unique biobank of high-quality clinical samples and data from cancer patients to support translational research. This effort, combined with cutting-edge molecular biology and clinical expertise, underscores the university's commitment to transforming cancer care.
About Oncodia AB
Oncodia is an innovative Medical Technology company based in Uppsala, Sweden. Oncodia is committed to providing in vitro diagnostic products that consistently meet customer needs, enhance patient treatment outcomes and adhere to regulatory and statutory requirements. Oncodia provides CE/IVD software for precision cancer medicine as well as CE/IVD products for DNA/RNA isolation from diagnostic tissue specimens. Their focus is to supply clinical pathology and oncology with the right solutions for optimal molecular diagnostics of solid tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com and STarsh@Renovarogroup.com
$RENB Renovaro Regains Compliance with NASDAQ Listing Requirement
Renovaro Inc
Fri, December 20, 2024 at 3:40 PM EST
In This Article:
RENB
+6.15%
Renovaro Inc
LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule, 5550(a)(2). The Company’s security will continue to be listed and traded on The Nasdaq Stock Market and this matter is now closed.
Renovaro previously received a notification letter from the Nasdaq Listing Qualifications Department on September 12, 2024, notifying the Company that, over the previous 30 consecutive business days, the closing bid price of the Company’s common stock had been below the minimum of $1.00 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and Renovaro Cube.
Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@Renovaro Cube.com and STarsh@Renovarogroup.com
David Weinstein, Chief Executive Officer of Renovaro, stated, “The potential for multi-cancer early detection screening and recurrence testing will be powered by AI chips that can process vast data sets. With this material step in acquiring the latest HPC capacity, Nebul and NVIDIA will help Renovaro in driving a vision towards a future where generic diagnostic scans for diseases can be done at any point of care with a single vial of blood, helping patients detect diseases early enough to get cured. This will help to massively reduce unnecessary treatments and address the soaring costs of care that are increasingly becoming a societal problem. We expect top-tier partnerships such as these will boost our technology’s visibility and potential, laying the foundation for our go-to-market strategy.”
As part of this initiative, Renovaro Cube plans to deploy a dedicated NVIDIA SuperPOD powered by NVIDIA DGX B200™ systems, which feature the latest Blackwell GPU’s, and apply NVIDIA Parabricks functionality to ensure optimal performance on the NVIDIA clusters. Each DGX B200 system delivers up to 72 petaFLOPS of training performance and 144 petaFLOPS of inference performance, providing the computational power necessary to integrate AI across medium-sized hospitals.
Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions
NEWS: Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection
Renovaro Inc
Fri, December 20, 2024 at 9:00 AM EST 7 min read
In This Article:
RENB
+5.16%
Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions
LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic collaboration with Nebul (www.nebul.com) a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases.
Nebul is a European NVIDIA NPN DGX Preferred Cloud Service Provider providing world-class supercomputing and GPU-accelerated business computing services, and a preferred cloud service provider in the NVIDIA Partner Network.
As part of this initiative, Renovaro Cube plans to deploy a dedicated NVIDIA SuperPOD powered by NVIDIA DGX B200™ systems, which feature the latest Blackwell GPU’s, and apply NVIDIA Parabricks functionality to ensure optimal performance on the NVIDIA clusters. Each DGX B200 system delivers up to 72 petaFLOPS of training performance and 144 petaFLOPS of inference performance, providing the computational power necessary to integrate AI across medium-sized hospitals.
The collaboration aims to harness cutting-edge AI technologies and high-performance computing (HPC) built on the latest technology available from NVIDIA to transform diagnostic and therapeutic methodologies. This important step follows on finalization of a pilot project confirming our processing capabilities of liquid biopsy samples on NVIDIA’s GPUs.
NVIDIA’s newest Blackwell GPUs are revolutionizing the speed of processing genomic data at molecular level, for example from blood (cfDNA), which is crucial for timely diagnosis and treatment selection. By leveraging their unparalleled computational efficiency, Renovaro Cube will further develop non-invasive liquid biopsy technologies using cfDNA and 3rd-generation sequencing to analyze and interpret massive cfDNA datasets at high speed, providing healthcare providers with actionable insights faster than ever before.
David Weinstein, Chief Executive Officer of Renovaro, stated, “The potential for multi-cancer early detection screening and recurrence testing will be powered by AI chips that can process vast data sets. With this material step in acquiring the latest HPC capacity, Nebul and NVIDIA will help Renovaro in driving a vision towards a future where generic diagnostic scans for diseases can be done at any point of care with a single vial of blood, helping patients detect diseases early enough to get cured. This will help to massively reduce unnecessary treatments and address the soaring costs of care that are increasingly becoming a societal problem. We expect top-tier partnerships such as these will boost our technology’s visibility and potential, laying the foundation for our go-to-market strategy.”
Nebul, recognized for its expertise in developing and managing large-scale AI infrastructure, will oversee the operation of this Superpod cluster. This collaboration extends to partnerships with institutions aiming to accelerate the adoption of AI in healthcare.
Arnold Juffer, Chief Executive Officer of Nebul, stated, “Supporting Renovaro in their mission to revolutionize healthcare through early detection and cancer diagnosis aligns well with Nebul’s mission to supply cutting-edge AI technology in healthcare. The NVIDIA partnership, combined with deep expertise, true GDPR and legal compliance is developing into a powerful force in European AI advancement. This validates Nebul’s approach into various European industries which value privacy, compliance and AI advancements. Nebul’s relentless customer intimacy and support provides a strong differentiator for partners and clients.”
Maurice van Tilburg, Renovaro's Chairman, added, "Renovaro Cube has worked on this project to utilize the compute capabilities of leading companies in this area. The partnership NVIDIA has with Nebul enhances our potential to drive true innovation in the health sector, particularly in the Netherlands and beyond."
About Nebul
Nebul offers an enterprise class European private AI cloud combined with the convenience, scale, and reach of big global hyper scalers into a genuine European Sovereign-Hybrid Cloud. Using the full range of NVIDIA technologies, new capabilities like Private AI, Digital Twins and Omniverse can be enabled more easily and quickly without sharing sensitive corporate data with third parties you do not control. Nebul Cloud enables AI development and operations using the latest technologies. From Generative AI to Digital Twins and Omniverse simulations, Nebul empowers European organizations to harness the power of AI securely and efficiently. Nebul has achieved NEN 7510 and ISO 27001 certifications, demonstrating compliance with stringent standards for securely processing European healthcare patient data, ensuring data confidentiality, integrity, and availability for AI applications. Nebul on the web: nebul.com
About Renovaro Cube
Renovaro Cube is a pioneer in AI-based molecular diagnostics, committed to revolutionizing healthcare through advanced data analysis. Its platform integrates cutting-edge AI capabilities with state-of-the-art HPC infrastructure to provide unparalleled insights into multi-omic data for early detection of diseases based on non-invasive testing using liquid biopsy (blood).
Renovaro Cube’s AI platform is purpose-built to process and analyze multi-omic molecular data, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. Originally awarded for its fintech application, this platform has been reengineered for healthcare, offering:
Sequence Processing: Transform raw molecular data from patient samples into clean, analyzable formats using advanced sequencing and alignment technologies, ensuring the highest quality for downstream analysis.
Biomarker Discovery: Harness unique algorithms and multi-omic pipelines to identify biologically relevant cancer biomarkers, providing critical insights into disease mechanisms and potential therapeutic targets.
AI Factory: Employ sophisticated machine learning models to predict cancer presence, origin, and stage based on extracted biomarker features. These models are trained on vast datasets to enhance accuracy and reliability, supporting early detection and personalized treatment strategies.
Precision Diagnostics: Offer an interactive interface for visualizing data, generating comprehensive clinical reports, and delivering actionable insights across various omic layers and biomarkers. This interface empowers healthcare professionals to make informed decisions with confidence.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and Renovaro Cube.
Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@Renovaro Cube.com and STarsh@Renovarogroup.com
$RENB More news: Diagnostic Poster: Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing (K. Roohollahi , A. Foster, E. Post ,D. Vessies, J. van den Berg, D. Makarawung, F. van Asch) https://renovarogroup.com/novel-insights-on-non-invasive-cancer-diagnostics-poster/
Excellent update: “The research demonstrates that Oxford Nanopore sequencing of cell-free DNA from blood plasma can effectively capture significant copy number alterations (CNAs), which characterize the copy number landscape of lung cancer tissues—traditionally assessed through tissue biopsy,” said Khashayar Roohollahi, senior scientist at RenovaroCube. $RENB
$RENB Great early morning news out.
$RENB News: RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.
This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patients. CNAs are a key hallmark of cancer and can be used in cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping.
“The research demonstrates that Oxford Nanopore sequencing of cell-free DNA from blood plasma can effectively capture significant copy number alterations (CNAs), which characterize the copy number landscape of lung cancer tissues—traditionally assessed through tissue biopsy,” said Khashayar Roohollahi, senior scientist at RenovaroCube.
Furthermore, CNAs can be used to estimate tumor fractions which is useful for predicting cancer progression and monitoring. The study emphasizes the potential of this technology in reducing the need for invasive tissue biopsies, a significant advancement in oncology.
Read more about the poster: https://renovarogroup.com/novel-insights-on-non-invasive-cancer-diagnostics-poster/
RenovaroCube remains committed to advancing precision medicine through innovative research and technologies, offering hope for more effective, patient-centered cancer care.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments utilizing non-invasive liquid biobsy. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.
About MAP
MAP focuses on current and emerging approaches in precision oncology, highlights successes and challenges, and proposes potential solutions in clinical research and practice.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com and STarsh@Renovarogroup.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTI1Nzg5NiM2NTM3ODEwIzIxMjA2Nzk=
https://ml.globenewswire.com/media/N2ExZjNkNDktODBhZC00MGRlLWE4OWItNjY5MWQ1ODYwOWNiLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
" Mr. Calder has more than 30 years of life science executive experience, having served in various senior executive roles for Florida-based biotechnology companies and research institutes including Viragen"
RENB new 52 week low
RENB 10Q 8 October
$RENB @Nasdaq Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform, Starting with Early Cancer Detection https://renovarobio.com/news/personalaize-and-cube-forge-groundbreaking-partnership-to-accelerate-ai-driven-healthcare-platform-and-point-of-care-diagnostics/
$RENB NEWS: PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics
Thu, September 19, 2024 at 9:00 AM EDT 5 min read
In This Article:RENB
Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes
AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.
Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”
Frank van Asch, Founder and CTO of RenovaroCube,” Together, we are pioneering a future where healthcare outcomes are improved by training models for multiple decisions through the entire health journey, ensuring the right accuracy for therapeutic decisions in every disease stage.”
The first phase of the collaboration focuses on establishing a strong foundation for the partnership, with PersonalAIze providing critical expertise in the integration of AI into healthcare. It will enhance existing collaborations with Academic and corporate partners and create new ones to build an eco-system to help develop and bring to the market a cutting-edge SaaS model and the next generation highly accurate diagnostics, starting with cancer.
Prof Sandjai Buhlai, Co-CEO and Co-Founder PersonalAIze: “This collaboration signals a bold step forward in utilizing the full potential of AI potentially to help revolutionize early-stage medical interventions and diagnosis at the earliest stage of cancer before imaging has been able to detect the tumors.”
Key contributions from PersonalAIze include:
Ethical AI: Ensuring the AI models are free from harmful biases and trained to support fairness and inclusivity in medical diagnostics.
Legal Guidance: Providing expert advice on legal responsibilities tied to AI outputs, including issues of AI accountability and potential liability.
Regulatory Compliance: Assisting in navigating existing and emerging regulations such as NEN, ISO, GDPR, and the AI Act, ensuring the platform adheres to all relevant healthcare regulations and clinical guidelines.
Medical and Diagnostic Input: Offering support in clinical validation in collaboration with medical scientists to ensure the AI is reliable and effective in real-world medical environments.
Explainable AI: Developing AI models that are transparent, fostering trust and confidence from both healthcare providers and patients.
Key Resources and Support from PersonalAIze
As part of the collaboration, PersonalAIze will contribute:
Expert Personnel: Including a Principal Investigator (PI) to lead clinical AI efforts, a project manager to coordinate the collaboration and a strategic advisor to oversee the scientific strategy and execution.
Research and Talent Capacity: Leveraging academic partnerships to ensure access to cutting-edge research and innovation and facilitating talent scouting to support the project’s development.
Academic Spin-Out Opportunities: Supporting the commercialization of academic research through potential spin-out ventures related to AI diagnostics.
Co-Development of AI Platform: Jointly developing a science-driven, evidence-based AI platform that meets rigorous clinical and regulatory standards.
Ongoing Research and Publications: Contributing to the body of research through support with peer-reviewed publications in collaboration with clinical experts that will help build trust within the medical community and among regulatory bodies.
Architecture and Strategy Guidance: Continuously advising on the platform’s architecture and strategic direction, ensuring it stays aligned with the latest industry trends and scientific advancements.
Trusted AI: Developing a trustworthy, explainable AI platform that inspires confidence among healthcare providers and patients through clear and transparent decision-making processes.
About PersonalAIze
PersonalAIze focuses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision-making systems as well as improvement of health care operations such as capacity planning.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$RENB Today's Update on RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection https://www.globenewswire.com/news-release/2024/09/17/2947497/0/en/Independent-Expert-Assessment-Validates-RenovaroCube-s-Potential-as-a-Groundbreaking-AI-Platform-Starting-with-Early-Cancer-Detection.html
$RENB News: Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based.
Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: “We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze’s expertise.”
Frank van Asch remarked on the collaboration, “The expertise of PersonalAIze’s team is exceptional, and their positive evaluation of our AI/ML platform is invaluable.”
RenovaroCube's AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.
The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.
In their analysis, PersonalAIze noted the platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform’s unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch’s leadership.
Based on these findings, PersonalAIze is eager to collaborate further with RenovaroCube to enhance and commercialize the platform.
PersonalAIze aims to contribute in several key areas:
Advancing AI models by leveraging the latest state-of-the-art techniques.
Supporting the professional growth of the software team.
Enhancing the explainability of AI models, engaging clinicians in model development.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
This partnership could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
About PersonalAIze
PersonalAIze focusses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision making systems as well as improvement of health care operations such as capacity planning.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTIzMTk2NCM2NDgyMzM1IzIxMjA2Nzk=
https://ml.globenewswire.com/media/ZGJkNzBkMGQtY2Y5ZC00OTJkLWFkNTYtMjAwZmFjZWQzZmQzLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
RENB under $2
RENB under $2
$RENB - Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection - NVIDIA (NASDAQ:NVDA)
https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer- Benzinga #Healthcare #Biopharma #AI #Computing #Power
$RENB Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy https://www.marketscreener.com/quote/stock/RENOVARO-INC-47536345/news/Renovaro-Amsterdam-UMC-Cancer-Center-Plan-to-Form-Joint-Venture-for-Cancer-Immunotherapy-46820158/ @Nasdaq @Marketscreener1 #collaboration
$RENB News! Renovaro, Inc. Announces $10 million in Equity Committed
Renovaro Inc
Fri, Jun 14, 2024, 9:06 AM EDT
In this article:
RENB
+1.40%
Renovaro Inc
LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage.
“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.”
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$RENB - Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection - NVIDIA (NASDAQ:NVDA)
https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer- Benzinga #Healthcare #Biopharma $NVDA #AI #Computing #Power
Impressive Short Squeeze Triggered for Cancer Immunotherapy Company Renovaro, Inc. (NASDAQ: RENB)
Click here:
https://markets.financialcontent.com/startribune/article/getnews-2024-6-10-impressive-short-squeeze-triggered-for-cancer-immunotherapy-company-renovaro-inc-nasdaq-renb
$RENB $1.66 +28.29% HOD $2.34 (Nasdaq) Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy https://seekingalpha.com/pr/19737436-renovaro-inc-and-amsterdam-umc-cancer-center-poised-to-advance-cancer-immunotherapy?source=content_type%3Areact%7Csection%3APress%20Releases%7Csection_asset%3APress%20Releases%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A1
$RENB Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy https://www.marketscreener.com/quote/stock/RENOVARO-INC-47536345/news/Renovaro-Amsterdam-UMC-Cancer-Center-Plan-to-Form-Joint-Venture-for-Cancer-Immunotherapy-46820158/ @Nasdaq @Marketscreener1 #collaboration
|
Followers
|
5
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
196
|
|
Created
|
12/02/17
|
Type
|
Free
|
| Moderators Trooperstocks | |||
Renovaro Inc.
Renovaro is driven by an unwavering commitment to revolutionize healthcare. Our primary objectives encompass pioneering advancements in AI, diagnostics and therapies for patients with cancer.
RenovaroCube
Renovaro Cube is commited to use liquid biopsies for the full patient journey.
RenovaroBio
RenovaroBio has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.
From Strength to Strength
Both RenovaroCube and RenovaroBio are at the forefront of oncology innovations, revolutionizing the field of cancer treatment. RenovaroBio is committed to a future where survival is increased the toxic effects of chemotherapy are eliminated. They are focused on developing next-generation diagnostics and immunotherapy, specifically dendritic cell-based therapy, as an alternative to chemotherapy.
RenovaroCube is dedicated to develop the next generation of diagnostics for early detection of the disease, treatment selection, response prediction and follow-up of disease spanning the full patient journey using only one simple vial of blood (liquid biopsies). Collectively we offer a holistic approach to cancer treatment, benefiting not only patients but also clinicians and healthcare providers by employing a vertically integrated approach.
Our mission
Integrating the power of AI from diagnosis through treatment and recovery
Our Goals
By fostering global collaborations, we seek to accelerate the translation of scientific breakthroughs into tangible solutions, positively impacting lives worldwide.
Renovaro is dedicated to creating a healthier and more resilient future for humanity through innovation, ethical practices, and a relentless pursuit of excellence in biotechnology.
To impact patients from diagnostics through theraputic intervention
A future free from toxic Chemotherapy
Detection of diseases before the appearance of symptoms
Non-invasive liquid biopsy testing
Our Team
COMMITTED TO RADICALLY ACCELERATE PRECISION MEDICINE
Maurice van Tilburg – Glimne
Chairman
David Weinstein
Director & Chief Executive Officer (CEO)
Douglas W. Calder
Director
Mark Collins, Phd
Director
James A. McNulty
Director
Simon Tarsh
Interim Chief Financial Officer (CFO)
Company
GEDiCube and Cyclomics Forge Alliance, Spearheading Global Liquid Biopsy Market
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
Cyclomics’ 4th generation liquid biopsy genomics platform is a truly “Omni-Omic” blood test ready for AI application
GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers.
GEDiCube’s partnership with NVIDIA’s Inception program will help expand to multi-modal capabilities by adding imaging.
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
“Our Omni-Omic technology was developed to help empower AI platforms and thereby transform non-invasive healthcare solutions to detect cancers and other diseases as early as possible. GEDiCube’s innovative deep learning algorithms have created robust multi-omics panels that perform remarkably well. Together, I believe we will change the field.”
“There is enormous power in applying AI to multiple omics data layers that can be detected from a vial of blood from every patient with cancer. I believe that integrating Cyclomics into GEDiCube will allow us to gain greater accuracy and widespread Omni-omic measurements through next-generation sequencing and enter the cancer monitoring market this year. I consider that to be a significant step towards bringing early detection of cancer to its inflection point.”
By Coenraad van Kalken, MD, PhD, the CEO of GEDiCube
About Cyclomics
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence, thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.
About GEDiCube
At GEDiCube, we are committed to the early detection of cancer, to intervene at a stage where treatment can be most effective. We have developed an award-winning AI Technology that significantly accelerates early cancer detection and diagnosis at an early stage and its recurrence via liquid biopsy. Our platform, “ The Cube,” brings together proprietary artificial intelligence (AI/ML) technology and algorithms, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to accelerate precision medicine and enable breakthrough changes in cancer care. As of this morning GEDiCube will operate under its new name, RenovaroCube.
Top Reasons to Have RENB on Your Radar RIGHT NOW
Cutting-Edge Innovation: Renovaro Biosciences is at the forefront of medical innovation, spearheading advanced allogeneic cell and gene therapies for cancer, HIV, and HBV.
Transforming Healthcare: By reshaping immune responses and aiming for a future free from toxic chemotherapy, RENB is driving transformative changes in healthcare, offering hope for millions worldwide.
Market Potential: With a focus on a multi-billion dollar market opportunity, RENB is strategically positioned to capitalize on significant growth prospects in the healthcare sector.
Clinical-Stage Advancements: As a clinical-stage company, RENB has made substantial progress in developing transformative therapies, with several candidates advancing through preclinical and clinical phases.
Cancer Treatment Revolution: RENB's groundbreaking therapies offer hope for patients battling cancer, with promising developments in solid tumor treatments that could revolutionize cancer care.
HIV Breakthroughs: With innovative approaches to gene-modified cell therapies for HIV, RENB is pioneering potential cures and preventive measures, addressing a critical need in global healthcare.
HBV Gene Therapy: RENB's exploration of gene therapy for HBV showcases its commitment to tackling infectious diseases, presenting a promising avenue for combating Hepatitis B virus infections.
Strategic Partnerships: Collaborations with renowned institutions like UCLA and the Fred Hutchinson Cancer Research Center underscore RENB's commitment to leveraging top-tier expertise in advancing its therapies.
Platform Technology: RENB's sophisticated allogeneic cell therapy platforms offer scalable and cost-effective solutions, enhancing accessibility and effectiveness in treating various diseases.
Investor Appeal: With a NASDAQ listing (NASDAQ: RENB), RENB presents an attractive investment opportunity, backed by its innovative pipeline, strategic partnerships, and potential for significant market growth.
The Opportunity…
Renovaro Biosciences Inc (NASDAQ: RENB) presents an unparalleled opportunity in the rapidly evolving landscape of healthcare innovation. With a focus on advanced allogeneic cell and gene therapies, RENB is poised to address critical unmet needs in the treatment and prevention of cancer, HIV, and HBV.
In a market with multi-billion dollar potential, RENB stands out as a pioneering force, leveraging cutting-edge technology to develop transformative therapies. Its clinical-stage advancements demonstrate tangible progress in bringing these therapies to fruition, offering hope for patients worldwide.
One of RENB's most promising areas of focus is its revolutionary approach to cancer treatment. By targeting solid tumors with genetically modified cell therapies, RENB aims to reshape the landscape of cancer care, potentially offering life-changing outcomes for patients. Moreover, its commitment to innovative HIV therapies reflects a dedication to addressing the ongoing challenges of managing this chronic disease, with the ultimate goal of achieving a cure.
The exploration of HBV gene therapy further underscores RENB's commitment to tackling infectious diseases, with the potential to impact millions affected by Hepatitis B virus infections. Through strategic partnerships with leading institutions such as UCLA and the Fred Hutchinson Cancer Research Center, RENB leverages top-tier expertise to drive forward its research and development efforts.
With a NASDAQ listing (NASDAQ: RENB), RENB offers investors a compelling opportunity to participate in the future of healthcare. Its innovative pipeline, strategic collaborations, and potential for significant market growth make RENB an attractive investment proposition. By transforming healthcare and offering hope for a future free from toxic chemotherapy, RENB is poised to make a profound impact on the lives of millions worldwide.
If there is a way to prevent this devastating disease from happening, it could completely change the healthcare landscape going forward. This is where Renovaro Biosciences Inc (NASDAQ: RENB) is leading in innovation.
Company Overview:
Renovaro Biosciences Inc. (NASDAQ: RENB) is a pioneering biotechnology company at the forefront of revolutionizing healthcare. Focused on developing advanced allogenic cell and gene therapies, Renovaro is committed to addressing significant unmet needs in cancer, HIV, and HBV treatment. With a strategic emphasis on innovative technologies and cutting-edge research, the company is reshaping the landscape of modern medicine.
Renovaro's mission is anchored in its dedication to transforming cancer care. By leveraging groundbreaking gene-modified cell therapies, the company aims to offer hope to patients battling solid tumors, a critical area where traditional treatments often fall short. Additionally, Renovaro's pioneering approach to HIV treatment presents a potential breakthrough in combating the virus and improving patient outcomes worldwide.
Committed to advancing healthcare, Renovaro collaborates with renowned institutions such as UCLA and the Fred Hutchinson Cancer Research Center. Through these strategic partnerships, the company accelerates the development of its therapies and maximizes their potential to impact patients' lives positively.
As a NASDAQ-listed company (NASDAQ: RENB), Renovaro offers investors a compelling opportunity to participate in the dynamic field of biotechnology. With a focus on innovation, collaboration, and market growth, Renovaro is poised to lead the way in transforming healthcare and shaping a brighter future for patients worldwide.
ADVANCED ALLOGENEIC CELL THERAPY
The strategic benefit of cell therapy platforms is to potentially allow for manufacture of large, “off-the-shelf” banks of therapeutic cells that could be accessed on demand by health care professionals to potentially decrease the time between diagnosis and treatment.
In addition, because we focus on cells from donors, the strategy could potentially enhance the ability of the therapeutic candidates to induce a more robust response once injected into patients. The human immune system is designed to recognize and distinguish “self” from “non-self” and destroy “otherness” such as bacteria, viruses, and damaged or diseased cells such as cancer cells. Alloreactivity (reacting against another person’s cells) is the most powerful response the immune system generates.
Several of our technologies take advantage of the alloreactivity to hyper stimulate a person’s immune response to better attack a chronic infection (e.g., HIV) or solid tumor. In certain proposed treatments in development (e.g., HIV and cancer), cells taken from healthy donors are sometimes genetically modified to introduce signaling molecules that are designed to enhance the ability of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.
Renovaro believes that the combination of off-the-shelf allogeneic cells, combined with genetic modifications designed to enhance immune signaling, could potentially generate therapeutic candidates that have unique attributes that will increase the likelihood of success.
CELL THERAPY ENABLING TECHNOLOGY
In addition to the platform described above, Renovaro has an innovative gene therapy approach to enhance the selection and engraftment (uptake) of cells carrying therapeutic attributes. Enhanced uptake or engraftment could play a critical role in some cases to increase the likelihood of therapeutic benefit. This technology was initially developed for autologous cell therapy from a person living with HIV, and genetically modifying those cells so they cannot be infected with most variants of HIV, plus a gene modification to enhance uptake. We have sublicensed under a profit-sharing agreement our technology to potentially increase engraftment for potential use in CAR-T therapy as a potential cure for HIV.
HBV GENE THERAPY
Renovaro is exploring various approaches for gene therapy design elements to potentially eliminate virus-infected cells with an innovative molecular mechanism that co-opts the virus’ machinery to induce the death of infected cells rather than reproducing and causing more infection and exacerbate disease.
LEVERAGING BANKED (OFF-THE-SHELF) ALLOGENIC CELL THERAPY
Leveraging allogenic cells offers numerous advantages to our development strategy:
Boosting Immunity: Non-self allogenic cells bolster T-Cells, activating immune responses effectively.
Enhanced Safety Potential: Allogenic cells, naturally rejected after stimulating cancer-killing cells, don't permanently reside in the body, possibly improving safety.
Expedited Therapy Access: Cryopreserved dendritic cell banks enable swift therapy post-diagnosis, reducing waiting times. Scalable production from a single donor source ensures cost-effectiveness compared to autologous cell therapy.
Versatile Platform: Our platform, primed to receive any tumor antigen, facilitates rapid development of multiple products for various cancer types
Renovaro BioSciences collaborates with Dr. Anahid Jewett from UCLA to further investigate the efficacy of our approach in pancreatic cancer. Dr. Jewett's innovative mouse model mimics the human immune system, offering invaluable insights for advancing cancer treatment.
Unmatched efficacy for therapeutic vaccines in preclinical models for human solid tumors
RENB-DC11 treated animals compared to controls
Untreated tumor
Tumor treated with untransduced Dendritic Cells (mainstream cancer vaccine approach)
Tumor treated with vector control transduced Dendritic Cells
80-90% decreases pancreas tumor size (weight and volume)
Significant infiltration of tumor sac by effector immune cells
Significant peripheral T and NK Cell immune activation
No metastases
Delayed injection of RENB-DC11 in mice with established luciferase labeled pancreas tumor, stopped progression and showed drastic tumor size regression in 2/3 mice (one mouse had no tumor detection 4wk post dosing), whereas all untreated mice showed massive tumor progression.
Revolutionizing Infectious Disease Treatment: Unveiling Renovaro Biosciences' Groundbreaking Platform for Combatting Viral Threats!
"Despite advances in treatment, HIV remains a global challenge. Antiretroviral therapy has transformed HIV from a death sentence to a manageable condition, yet it comes with challenges such as lifelong therapy, high costs, and risks of side effects. With drug resistance on the rise, there's a critical need for innovative solutions. Stigma and discrimination further complicate the situation.
Over 40% of those needing therapy lack access, and HIV claims over a million lives annually with millions more newly infected. A cure or preventive vaccine holds the promise of transforming countless lives worldwide."
RENB-HV-12: PREVENTIVE AND THERAPEUTIC VACCINES
Allogeneic Cell Therapy Platform
Renovaro BioSciences aims to boost the immune system against HIV through vaccination, offering protection for uninfected individuals and potentially controlling the virus in those already infected. Their innovative approach utilizes immune response induction from donor cells. Promising in vitro results have led to non-human primate studies at the Fred Hutchinson Cancer Research Center, with preliminary findings expected by late 2023. Human studies could follow in late 2024
RENB-HV01: AUTOLOGOUS TRANSPLANT WITH GENETICALLY MODIFIED CELLS
"Renovaro BioSciences presents a groundbreaking solution for HIV treatment by targeting CCR5 expression, crucial for HIV entry into cells. Their ALDH gene modification technology aims to enhance engraftment of gene-modified stem cells without the need for immune system ablation, potentially eliminating the need for Antiretroviral Treatment (ART). While initial studies showed promising results, further development of RENB-HV01 was deemed costly. As a strategic move, Renovaro sub-licensed the ALDH gene modification to Caring Cross, who aims to integrate it into their CAR-T cell therapy for enhanced engraftment."
RENB-HV21: IMMUNOTHERAPY WITH ALLOGENEIC NK/GDT CELLS
Allogeneic Cell Therapy Platform
"Renovaro BioSciences is exploring RENB-HV21, a promising HIV treatment utilizing allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). These cells, believed to play a key role in controlling the virus, offer innovative potential for HIV therapy. Renovaro holds an exclusive license for the underlying patent, with successful pre-IND studies completed. However, due to priority shifts to the Oncology pipeline, immediate clinical trials for RENB-HV21 are not planned."
HBV:
RENB-HB01: HBV Gene Therapy
RENB-HB-01 is currently in the early pre-clinical phase, with ongoing exploration of different gene therapy design approaches. Pending successful results from these explorations, we anticipate initiating the regulatory process by the first half of 2024. However, our primary focus and investment priority lie in advancing the oncology platform, starting with pancreatic cancer research and development.
Renovaro Biosciences Targets Expansive Market Opportunities
Renovaro Biosciences: Pioneering Breakthroughs in Pipeline and Technology Platforms
Our integrated platforms encompass innovative interventions in advanced cell and gene therapies that provide hope for cures and/or life-long remissions for devastating diseases. Because of the relative ease of administration, our potentially ground-breaking interventions could be used throughout the world to transform the lives of millions of people.
Revolutionizing Cancer Treatment: Explore Renovaro Biosciences' Innovative Oncology Platform
GENE MODIFIED CELL THERAPIES FOR CANCER / SOLID TUMORS
Currently into IND-enabling phase with planned IND submission H2 2024
Renovaro Biosciences pioneers cutting-edge cancer therapies targeting immune evasion. Our innovative approach, leveraging genetically engineered dendritic cells, bypasses tumor defenses, and enhances tumor eradication. RENB-DC11, a breakthrough therapy, harnesses genetic modifications to bolster immune signaling, effectively targeting aggressive solid tumors.
“The fusion of AI and biotech opens up new horizons in healthcare. We have been advancing strategic partnerships with leading academic centers and technology companies while working to expand our existing relationship with NVIDIA. We believe our combined capabilities will help to accelerate both the ability to detect and treat cancer and other diseases.”
By Dr. van Kalken added,
In summary…
In the realm of modern medicine, the quest to conquer cancer and infectious diseases stands as one of humanity's greatest challenges. Renovaro Biosciences Inc. (NASDAQ: RENB) emerges as a beacon of hope, dedicated to pioneering advanced allogenic cell and gene therapies to combat these formidable foes.
With a comprehensive pipeline spanning oncology, HIV, and HBV, Renovaro is at the forefront of cutting-edge medical innovation. In the oncology sphere, the company's groundbreaking platform targets solid tumors, leveraging genetically modified dendritic cells to bypass immune evasion and enhance tumor eradication. Promising preclinical results from RENB-DC11 demonstrate its efficacy against aggressive forms of solid tumors.
In the battle against HIV, Renovaro's innovative approach seeks to boost immune responses through preventive and therapeutic vaccines, potentially transforming the lives of millions worldwide. Meanwhile, their exploration of allogenic Natural Killer and Gamma Delta T-Cells presents a novel avenue for HIV treatment.
Additionally, Renovaro's foray into HBV gene therapy signals a promising step towards eradicating virus-infected cells, offering hope for those afflicted by this persistent infection.
With a focus on leveraging banked allogenic cell therapy and strategic collaborations with esteemed institutions like UCLA, Renovaro is poised to revolutionize healthcare delivery. As the company advances its mission to develop definitive cures and therapies, now is the time to keep Renovaro Biosciences Inc. on your radar as a leading force in the fight against cancer and infectious diseases.
Disclaimer
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here.
AI
